BioMarin Pharmaceutical Inc. Stock Predictions
Currently predicting for Mon, 3 Apr 2023Trading levels for BMRN
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 98.97 | 1.78 % | |
| R2 | 98.15 | 0.94 % | ||
| R1 | 97.65 | 0.419 % | ||
| Current price: | 97.24 | |||
| Support | S1 | 96.02 | -1.26 % | |
| S2 | 95.51 | -1.78 % | ||
| S3 | 94.70 | -2.62 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 111.40 | 14.56 % | |
| R2 | 106.92 | 9.95 % | ||
| R1 | 99.59 | 2.42 % | ||
| Current price | 97.24 | |||
| Support | S1 | 94.30 | -3.02% | |
| S2 | 93.42 | -3.93% | ||
| S3 | 93.41 | -3.94% |
BMRN Predictions History
5 months ago
Auto.StockinvestBot predicted that
BMRN
for 2022-10-14 is going
$88.23 (1.12%)
5 months ago
Robo.StockinvestBot predicted that
BMRN
for 2022-10-14 is going
$86.31 (-1.08%)
5 months ago
fr46rz4q49.335603 predicted that
BMRN
for 2022-10-14 is going
3 years ago
Todor Lapkov predicted that
BMRN
for 2020-03-03 is going
$95.16 (2.63%)
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o... BMRN Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
